Early versus delayed tumor specific therapy and survival in patients with lung cancer: a retrospective study

Rike Geiken-Weinstock; Anna K L Reyners; Frank Griesinger; Burkhard Joerg Otremba; Michael Hoheisel; Jörg Bäsecke

doi:10.1159/000530574

Early versus delayed tumor specific therapy and survival in patients with lung cancer: a retrospective study

Rike Geiken-Weinstock, Anna K L Reyners, Frank Griesinger, Burkhard Joerg Otremba, Michael Hoheisel, Jörg Bäsecke^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

67 Downloads (Pure)

Abstract

INTRODUCTION: The timing of tumor specific palliative therapy and its influence on the survival of patients with stage IV lung cancer remains unclear.

METHODS: 375 patients with stage IV lung cancer who experienced an early or delayed therapy (early or delayed therapy group; TG) were investigated using histology and ECOG performance score-related (ECOG-PS) subgroups. Kaplan-Meier and Cox regression analyses were used for survival analyses.

RESULTS: Patients in the early TG had a significantly shorter median overall survival (OS) than those in the delayed TG (6 vs. 11 months). Patients with an ECOG-PS of ≥1 were significantly more present in the early than in the delayed TG (66.8% vs. 51.9%). But an early therapy was also significantly associated to a shorter median OS in ECOG-matched subgroups (ECOG-PS of 0; 7 vs. 23 months, ECOG >1 ; 6 vs. 8 months). An early therapy was associated to a significantly worse median OS in histological subgroups (NSCLC; 5 vs. 11 months, SCLC; 7 vs. 11 months) and was an independent risk factor in uni- and multivariate analyses.

CONCLUSIONS: An early initiation of cancer specific therapy was associated with a shorter survival time in palliative lung cancer patients, independent of the ECOG-PS and histological subtype.

Original language	English
Pages (from-to)	227–235
Number of pages	18
Journal	Oncology Research and Treatment
Volume	46
Issue number	6
Early online date	13-Apr-2023
DOIs	https://doi.org/10.1159/000530574
Publication status	Published - Jun-2023

Access to Document

10.1159/000530574

Early versus Delayed Tumor-Specific Therapy and Survival in Patients with Lung CancerFinal publisher's version, 829 KBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{5dac23b1451a46d1a9eb3cac08871e91,

title = "Early versus delayed tumor specific therapy and survival in patients with lung cancer: a retrospective study",

abstract = "INTRODUCTION: The timing of tumor specific palliative therapy and its influence on the survival of patients with stage IV lung cancer remains unclear.METHODS: 375 patients with stage IV lung cancer who experienced an early or delayed therapy (early or delayed therapy group; TG) were investigated using histology and ECOG performance score-related (ECOG-PS) subgroups. Kaplan-Meier and Cox regression analyses were used for survival analyses.RESULTS: Patients in the early TG had a significantly shorter median overall survival (OS) than those in the delayed TG (6 vs. 11 months). Patients with an ECOG-PS of ≥1 were significantly more present in the early than in the delayed TG (66.8% vs. 51.9%). But an early therapy was also significantly associated to a shorter median OS in ECOG-matched subgroups (ECOG-PS of 0; 7 vs. 23 months, ECOG >1 ; 6 vs. 8 months). An early therapy was associated to a significantly worse median OS in histological subgroups (NSCLC; 5 vs. 11 months, SCLC; 7 vs. 11 months) and was an independent risk factor in uni- and multivariate analyses.CONCLUSIONS: An early initiation of cancer specific therapy was associated with a shorter survival time in palliative lung cancer patients, independent of the ECOG-PS and histological subtype.",

author = "Rike Geiken-Weinstock and Reyners, {Anna K L} and Frank Griesinger and Otremba, {Burkhard Joerg} and Michael Hoheisel and J{\"o}rg B{\"a}secke",

note = "S. Karger AG, Basel.",

year = "2023",

month = jun,

doi = "10.1159/000530574",

language = "English",

volume = "46",

pages = "227–235",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "KARGER",

number = "6",

}

TY - JOUR

T1 - Early versus delayed tumor specific therapy and survival in patients with lung cancer

T2 - a retrospective study

AU - Geiken-Weinstock, Rike

AU - Reyners, Anna K L

AU - Griesinger, Frank

AU - Otremba, Burkhard Joerg

AU - Hoheisel, Michael

AU - Bäsecke, Jörg

N1 - S. Karger AG, Basel.

PY - 2023/6

Y1 - 2023/6

N2 - INTRODUCTION: The timing of tumor specific palliative therapy and its influence on the survival of patients with stage IV lung cancer remains unclear.METHODS: 375 patients with stage IV lung cancer who experienced an early or delayed therapy (early or delayed therapy group; TG) were investigated using histology and ECOG performance score-related (ECOG-PS) subgroups. Kaplan-Meier and Cox regression analyses were used for survival analyses.RESULTS: Patients in the early TG had a significantly shorter median overall survival (OS) than those in the delayed TG (6 vs. 11 months). Patients with an ECOG-PS of ≥1 were significantly more present in the early than in the delayed TG (66.8% vs. 51.9%). But an early therapy was also significantly associated to a shorter median OS in ECOG-matched subgroups (ECOG-PS of 0; 7 vs. 23 months, ECOG >1 ; 6 vs. 8 months). An early therapy was associated to a significantly worse median OS in histological subgroups (NSCLC; 5 vs. 11 months, SCLC; 7 vs. 11 months) and was an independent risk factor in uni- and multivariate analyses.CONCLUSIONS: An early initiation of cancer specific therapy was associated with a shorter survival time in palliative lung cancer patients, independent of the ECOG-PS and histological subtype.

AB - INTRODUCTION: The timing of tumor specific palliative therapy and its influence on the survival of patients with stage IV lung cancer remains unclear.METHODS: 375 patients with stage IV lung cancer who experienced an early or delayed therapy (early or delayed therapy group; TG) were investigated using histology and ECOG performance score-related (ECOG-PS) subgroups. Kaplan-Meier and Cox regression analyses were used for survival analyses.RESULTS: Patients in the early TG had a significantly shorter median overall survival (OS) than those in the delayed TG (6 vs. 11 months). Patients with an ECOG-PS of ≥1 were significantly more present in the early than in the delayed TG (66.8% vs. 51.9%). But an early therapy was also significantly associated to a shorter median OS in ECOG-matched subgroups (ECOG-PS of 0; 7 vs. 23 months, ECOG >1 ; 6 vs. 8 months). An early therapy was associated to a significantly worse median OS in histological subgroups (NSCLC; 5 vs. 11 months, SCLC; 7 vs. 11 months) and was an independent risk factor in uni- and multivariate analyses.CONCLUSIONS: An early initiation of cancer specific therapy was associated with a shorter survival time in palliative lung cancer patients, independent of the ECOG-PS and histological subtype.

U2 - 10.1159/000530574

DO - 10.1159/000530574

M3 - Article

C2 - 37054696

SN - 2296-5270

VL - 46

SP - 227

EP - 235

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

IS - 6

ER -

Early versus delayed tumor specific therapy and survival in patients with lung cancer: a retrospective study

Abstract

Access to Document

Handle.net

Fingerprint

Cite this